Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.33 |
| ▸ | GABRP | O00591 | 3/20 | 0.33 |
| ▸ | GABRD | O14764 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.33 |
| ▸ | GABRE | P78334 | 3/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072258 | 0.89 | CES2 (0.38) | PDE2AALDH1A1 | |
| SCHEMBL8737614 | 0.87 | PDE2A (0.50) | PDE2ASMN1; SMN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL16405335 | 0.82 | RAPGEF4 (0.35) | PDE2A | |
| SCHEMBL21139479 | 0.80 | PDE2A (0.41) | PDE2A | |
| SCHEMBL13799252 | 0.80 | PDE2A (0.33) | PDE2AGABRB3GABRA1GABRG2P2RX7 | |
| SCHEMBL15958518 | 0.80 | PDE2A (0.44) | PDE2ASMN1; SMN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL24986389 | 0.79 | PDE2A (0.41) | PDE2AKMT2AKDM4EALDH1A1GABRA2 | |
| SCHEMBL24986405 | 0.78 | PDE2A (0.43) | PDE2ASMN1; SMN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL24986404 | 0.78 | PDE2A (0.43) | PDE2ASMN1; SMN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL4088512 | 0.78 | CES2 (0.39) | PDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2021-04-15 | — | — | US | disclosed |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | PDE2A 1045/4885SMN1; SMN2 3571/4885KMT2A 4588/4885 |
| US-20190300526-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | PDE2A 1246/4885SMN1; SMN2 2456/4885KMT2A 4404/4885 |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | PDE2A 1045/4885SMN1; SMN2 3571/4885KMT2A 4588/4885 |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | PDE2A 1246/4885SMN1; SMN2 2456/4885KMT2A 4404/4885 |
| US-20210106568-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | PDE2A 1045/4885SMN1; SMN2 3571/4885KMT2A 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.